Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled cisplatin in stage IV NSCLC patients.

With the educational support of:

You may also be interested in:

A network meta-analysis of perioperative IO for resectable NSCLC

FLAURA2 post-progression outcomes

Updated safety data of AEGEAN study

Tags:

poster